English
简体中文
Total: £ 56.28
Published Date: 2025-01-13 | Pages: 81 | Tables: 85 | Pharma & Healthcare
The global market for Drugs for Vulvovaginal Candidiasis was valued at US$ 841 million in the year 2024 and is projected to reach a revised size of US$ 932 million by 2031, growing at a CAGR of 1.5% during the forecast period.
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
The Asia-Pacific region is the world"s largest market, with a market share of about 45%, followed by North America with nearly 20%
Report Scope
This report aims to provide a comprehensive presentation of the global market for Drugs for Vulvovaginal Candidiasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Vulvovaginal Candidiasis.
The Drugs for Vulvovaginal Candidiasis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs for Vulvovaginal Candidiasis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Vulvovaginal Candidiasis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Segment by Type
Cream
Pessary
Other
Segment by Application
Hospital & Clinic
Pharmacy
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Drugs for Vulvovaginal Candidiasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Drugs for Vulvovaginal Candidiasis Market Overview
1.1 Product Definition
1.2 Drugs for Vulvovaginal Candidiasis by Type
1.2.1 Global Drugs for Vulvovaginal Candidiasis Market Value Comparison by Type (2024 VS 2031)
1.2.2 Cream
1.2.3 Pessary
1.2.4 Other
1.3 Drugs for Vulvovaginal Candidiasis by Application
1.3.1 Global Drugs for Vulvovaginal Candidiasis Market Value by Application (2024 VS 2031)
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Global Drugs for Vulvovaginal Candidiasis Market Size Estimates and Forecasts
1.4.1 Global Drugs for Vulvovaginal Candidiasis Revenue 2020-2031
1.4.2 Global Drugs for Vulvovaginal Candidiasis Sales 2020-2031
1.4.3 Global Drugs for Vulvovaginal Candidiasis Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Drugs for Vulvovaginal Candidiasis Market Competition by Manufacturers
2.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers (2020-2025)
2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Drugs for Vulvovaginal Candidiasis, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Product Type & Application
2.7 Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Date of Enter into This Industry
2.8 Global Drugs for Vulvovaginal Candidiasis Market Competitive Situation and Trends
2.8.1 Global Drugs for Vulvovaginal Candidiasis Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue
2.8.3 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drugs for Vulvovaginal Candidiasis Market Scenario by Region
3.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2020-2031
3.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2020-2025
3.2.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2026-2031
3.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2020-2031
3.3.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2020-2025
3.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2026-2031
3.4 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.4.1 North America Drugs for Vulvovaginal Candidiasis Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
3.4.3 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.5.1 Europe Drugs for Vulvovaginal Candidiasis Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
3.5.3 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Region
3.6.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2031)
3.6.3 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.7.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
3.7.3 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
3.8.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2031)
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2026-2031)
4.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2031)
4.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2020-2031)
4.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2020-2025)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2026-2031)
4.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2020-2031)
4.3 Global Drugs for Vulvovaginal Candidiasis Price by Type (2020-2031)
5 Segment by Application
5.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2031)
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
5.1.2 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2026-2031)
5.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2031)
5.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2020-2031)
5.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2020-2025)
5.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2026-2031)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2020-2031)
5.3 Global Drugs for Vulvovaginal Candidiasis Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Perrigo
6.2.1 Perrigo Company Information
6.2.2 Perrigo Description and Business Overview
6.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio
6.2.5 Perrigo Recent Developments/Updates
6.3 J & J
6.3.1 J & J Company Information
6.3.2 J & J Description and Business Overview
6.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
6.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Portfolio
6.3.5 J & J Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Company Information
6.5.2 Bristol-Myers Squibb Description and Business Overview
6.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio
6.5.5 Bristol-Myers Squibb Recent Developments/Updates
6.6 Effik
6.6.1 Effik Company Information
6.6.2 Effik Description and Business Overview
6.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Portfolio
6.6.5 Effik Recent Developments/Updates
6.7 Teva
6.7.1 Teva Company Information
6.7.2 Teva Description and Business Overview
6.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Teva Drugs for Vulvovaginal Candidiasis Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Sanofi
6.8.1 Sanofi Company Information
6.8.2 Sanofi Description and Business Overview
6.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio
6.8.5 Sanofi Recent Developments/Updates
6.9 Cisen Pharmaceutical
6.9.1 Cisen Pharmaceutical Company Information
6.9.2 Cisen Pharmaceutical Description and Business Overview
6.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio
6.9.5 Cisen Pharmaceutical Recent Developments/Updates
6.10 Kingyork Group
6.10.1 Kingyork Group Company Information
6.10.2 Kingyork Group Description and Business Overview
6.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio
6.10.5 Kingyork Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis
7.2 Drugs for Vulvovaginal Candidiasis Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Vulvovaginal Candidiasis Production Mode & Process Analysis
7.4 Drugs for Vulvovaginal Candidiasis Sales and Marketing
7.4.1 Drugs for Vulvovaginal Candidiasis Sales Channels
7.4.2 Drugs for Vulvovaginal Candidiasis Distributors
7.5 Drugs for Vulvovaginal Candidiasis Customer Analysis
8 Drugs for Vulvovaginal Candidiasis Market Dynamics
8.1 Drugs for Vulvovaginal Candidiasis Industry Trends
8.2 Drugs for Vulvovaginal Candidiasis Market Drivers
8.3 Drugs for Vulvovaginal Candidiasis Market Challenges
8.4 Drugs for Vulvovaginal Candidiasis Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Drugs for Vulvovaginal Candidiasis Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Drugs for Vulvovaginal Candidiasis Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Drugs for Vulvovaginal Candidiasis Market Competitive Situation by Manufacturers in 2024
Table 4. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Drugs for Vulvovaginal Candidiasis Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Drugs for Vulvovaginal Candidiasis, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Product Type & Application
Table 12. Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2025) & (K Units)
Table 18. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2020-2025)
Table 19. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2026-2031) & (K Units)
Table 20. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2026-2031)
Table 21. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2020-2025)
Table 23. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2026-2031)
Table 25. North America Drugs for Vulvovaginal Candidiasis Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 27. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 28. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 32. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 33. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2020-2025)
Table 51. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2026-2031)
Table 52. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Table 53. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2026-2031)
Table 54. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2020-2025)
Table 57. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2026-2031)
Table 58. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2020-2025)
Table 59. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2026-2031)
Table 60. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2020-2025)
Table 61. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2026-2031)
Table 62. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Table 63. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2026-2031)
Table 64. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2020-2025)
Table 67. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2026-2031)
Table 68. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2020-2025)
Table 69. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2026-2031)
Table 70. Bayer Company Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. Bayer Drugs for Vulvovaginal Candidiasis Product
Table 74. Bayer Recent Developments/Updates
Table 75. Perrigo Company Information
Table 76. Perrigo Description and Business Overview
Table 77. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Perrigo Drugs for Vulvovaginal Candidiasis Product
Table 79. Perrigo Recent Developments/Updates
Table 80. J & J Company Information
Table 81. J & J Description and Business Overview
Table 82. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. J & J Drugs for Vulvovaginal Candidiasis Product
Table 84. J & J Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Pfizer Drugs for Vulvovaginal Candidiasis Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Bristol-Myers Squibb Company Information
Table 91. Bristol-Myers Squibb Description and Business Overview
Table 92. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product
Table 94. Bristol-Myers Squibb Recent Developments/Updates
Table 95. Effik Company Information
Table 96. Effik Description and Business Overview
Table 97. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Effik Drugs for Vulvovaginal Candidiasis Product
Table 99. Effik Recent Developments/Updates
Table 100. Teva Company Information
Table 101. Teva Description and Business Overview
Table 102. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Teva Drugs for Vulvovaginal Candidiasis Product
Table 104. Teva Recent Developments/Updates
Table 105. Sanofi Company Information
Table 106. Sanofi Description and Business Overview
Table 107. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Sanofi Drugs for Vulvovaginal Candidiasis Product
Table 109. Sanofi Recent Developments/Updates
Table 110. Cisen Pharmaceutical Company Information
Table 111. Cisen Pharmaceutical Description and Business Overview
Table 112. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product
Table 114. Cisen Pharmaceutical Recent Developments/Updates
Table 115. Kingyork Group Company Information
Table 116. Kingyork Group Description and Business Overview
Table 117. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Kingyork Group Drugs for Vulvovaginal Candidiasis Product
Table 119. Kingyork Group Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Drugs for Vulvovaginal Candidiasis Distributors List
Table 123. Drugs for Vulvovaginal Candidiasis Customers List
Table 124. Drugs for Vulvovaginal Candidiasis Market Trends
Table 125. Drugs for Vulvovaginal Candidiasis Market Drivers
Table 126. Drugs for Vulvovaginal Candidiasis Market Challenges
Table 127. Drugs for Vulvovaginal Candidiasis Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Product Picture of Drugs for Vulvovaginal Candidiasis
Figure 2. Global Drugs for Vulvovaginal Candidiasis Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Drugs for Vulvovaginal Candidiasis Market Share by Type: 2024 & 2031
Figure 4. Cream Product Picture
Figure 5. Pessary Product Picture
Figure 6. Other Product Picture
Figure 7. Global Drugs for Vulvovaginal Candidiasis Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Drugs for Vulvovaginal Candidiasis Market Share by Application: 2024 & 2031
Figure 9. Hospital & Clinic
Figure 10. Pharmacy
Figure 11. Global Drugs for Vulvovaginal Candidiasis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Drugs for Vulvovaginal Candidiasis Market Size (2020-2031) & (US$ Million)
Figure 13. Global Drugs for Vulvovaginal Candidiasis Sales (2020-2031) & (K Units)
Figure 14. Global Drugs for Vulvovaginal Candidiasis Average Price (USD/Unit) & (2020-2031)
Figure 15. Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure 16. Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturers in 2024
Figure 17. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers in 2024
Figure 18. Global 5 and 10 Largest Drugs for Vulvovaginal Candidiasis Players: Market Share by Revenue in Drugs for Vulvovaginal Candidiasis in 2024
Figure 19. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 20. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 21. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2020-2031)
Figure 22. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2020-2031)
Figure 23. U.S. Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 24. Canada Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2020-2031)
Figure 26. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2020-2031)
Figure 27. Germany Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. France Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. U.K. Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Italy Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Russia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2020-2031)
Figure 33. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2020-2031)
Figure 34. China Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Japan Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. South Korea Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. India Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Australia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. China Taiwan Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Indonesia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Thailand Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Malaysia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Philippines Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2020-2031)
Figure 45. Latin America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2020-2031)
Figure 51. Turkey Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. U.A.E Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Global Sales Market Share of Drugs for Vulvovaginal Candidiasis by Type (2020-2031)
Figure 55. Global Revenue Market Share of Drugs for Vulvovaginal Candidiasis by Type (2020-2031)
Figure 56. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2020-2031)
Figure 57. Global Sales Market Share of Drugs for Vulvovaginal Candidiasis by Application (2020-2031)
Figure 58. Global Revenue Market Share of Drugs for Vulvovaginal Candidiasis by Application (2020-2031)
Figure 59. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2020-2031)
Figure 60. Drugs for Vulvovaginal Candidiasis Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
